Region Hovedstaden — Sponsor Intelligence | 38 EU Trials

Filter these 38 trials by condition, phase, country and more.

Open in Search →

38 Registered trials

23 Recruiting

7 Completed trials

6 Countries active

91 Unique IMPs

100% Results reported

Phase II

Phase IV

Phase III: 1 Phase II/III: 3 Phase II: 14 Phase I/II: 2 Phase III/IV: 2 Phase IV: 12 Phase I: 1 Phase I (Other): 3

100%

7 of 7 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Angiosarcoma 1 Obesity 1 Childhood asthma 1 Basal cell carcinoma 1

Top IMPs

SEMAGLUTIDE 4 SODIUM CHLORIDE 4 IPILIMUMAB 3 NIVOLUMAB 3 PEMBROLIZUMAB 3 DENOSUMAB 2 ACETAZOLAMIDE 1 ALECTINIB HYDROCHLORIDE 1 AMOXICILLIN, CLAVULANIC ACID 1 AMPICILLIN 1 BLEOMYCIN 1 CABOZANTINIB 1

All trials

38 total

Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer Pending

2025-522431-34-00 Phase II 1 country TRASTUZUMAB, PERTUZUMAB
COMPASS - COpenhagen MenoPAuSe Study Pending

2025-522558-37-00 Phase II 1 country ESTRADIOL HEMIHYDRATE; SODIUM CHLORIDE; TESTOSTERONE; TRIPTORELIN
OV-PRIME-R (Oncolytic Virotherapy to enhance PReoperative IMmunotherapy Efficacy in patients with proficient mismatch repair (pMMR) Rectal c… Pending

2025-524375-23-00 Phase I (Other) 1 country
Neoadjuvant nivolumab and ipilimumab for patients with high-risk uveal melanoma Pending

2025-524953-15-00 Phase I (Other) 1 country
CALIBRATE Pending

2026-525547-32-01 Phase IV 1 country
The GranStone Trial Pending

2026-525608-85-00 Phase II/III 1 country
Rituximab for Treatment of Checkpoint Inhibitor Induced Immune Related Adverse Events Pending

2026-525728-18-00 Phase I (Other) 1 country
IMPACT-NAC: A clinical trial of N-acetylcysteine for adults with severe infection and liver dysfunction Pending

2026-525895-25-00 Phase IV 1 country
A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder Recruiting

2025-524163-21-00 Phase II 1 country SEMAGLUTIDE; SODIUM CHLORIDE
The M-bipolar RCT Recruiting

2025-523549-92-00 Phase III/IV 1 country MELATONIN
Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy (FLEET): A Randomized Controlled Trial Recruiting

2025-522506-20-00 Phase IV 1 country
Nitroglycerin for Esophageal Food Impaction Recruiting

2023-503983-17-00 Phase II 1 country GLYCERYL TRINITRATE
The effects of intravenous iron on mobility in elderly patients following hip fracture surgery: a multicentre, parallel group, randomised, c… Recruiting

2024-515116-42-00 Phase IV 1 country FERRIC DERISOMALTOSE; SODIUM CHLORIDE
Sema.Mood Recruiting

2024-511734-13-04 Phase III/IV 1 country SEMAGLUTIDE; SODIUM CHLORIDE
Advancing the quality of treatment and care for acute agitation in emergency psychiatry Recruiting

2023-510201-18-00 Phase II/III 1 country DEXMEDETOMIDINE; LORAZEPAM; MIDAZOLAM
Brachial plexus nerve block for closed reduction of distal radius fracture Recruiting

2024-512191-35-00 Phase IV 1 country EPINEPHRINE, LIDOCAINE HYDROCHLORIDE
Colchicine for ischemia with no obstructive coronary artery disease and microvascular dysfunction Recruiting

2023-507981-17-00 Phase II 1 country COLCHICINE
Biomarkers in clozapine-responding schizophrenia Recruiting

2024-515338-34-01 Phase IV 1 country
OPTIMAL DIURETIC THERAPIES FOR ACUTE HEART FAILURE WITH VOLUME OVERLOAD Recruiting

2024-510633-17-00 Phase III 1 country ACETAZOLAMIDE
Short course antibiotic treatment of Gram-negative bacteremia: A multicenter, randomized, non-blinded, non-inferiority interventional study Recruiting

2024-514900-16-00 Phase IV 1 country AMOXICILLIN, CLAVULANIC ACID; AMPICILLIN; CEFTAZIDIME; CIPROFLOXACIN; ERTAPENEM …
Azithromycin for treatment of hospitalized children with asthmatic symptoms Recruiting

2024-512605-29-01 Phase II 1 country
Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomiz… Recruiting

2024-511730-12-00 Phase II 1 country
The LiLa-Bipolar RCT Recruiting

2023-509607-32-00 Phase IV 1 country LAMOTRIGINE; LITHIUM CARBONATE
FIT-HF - Effect of weight loss on physical and cardiac performance in patients with heart failure and obesity Recruiting

2023-503753-35-01 Phase II 1 country SEMAGLUTIDE

Showing 1–24 of 38 trials

← All sponsors A–Z